Skip to main content

Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE

Clinical Trial Grant
Duke Scholars

Awarded By

Celgene Corporation

Start Date

May 3, 2024

End Date

April 7, 2029
 

Awarded By

Celgene Corporation

Start Date

May 3, 2024

End Date

April 7, 2029